213 related articles for article (PubMed ID: 25529015)
1. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients.
Niyazi M; Jansen NL; Rottler M; Ganswindt U; Belka C
Radiat Oncol; 2014 Dec; 9():299. PubMed ID: 25529015
[TBL] [Abstract][Full Text] [Related]
2. Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Fleischmann DF; Unterrainer M; Corradini S; Rottler M; Förster S; la Fougère C; Siepmann T; Schwaiger M; Bartenstein P; Belka C; Albert NL; Niyazi M
PLoS One; 2019; 14(7):e0216111. PubMed ID: 31339892
[TBL] [Abstract][Full Text] [Related]
3. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.
Flieger M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; la Fougère C; Ertl L; Linn J; Herrlinger U; Belka C; Niyazi M
J Neurooncol; 2014 Apr; 117(2):337-45. PubMed ID: 24504501
[TBL] [Abstract][Full Text] [Related]
4. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
[TBL] [Abstract][Full Text] [Related]
5. Irradiation and bevacizumab in high-grade glioma retreatment settings.
Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
[TBL] [Abstract][Full Text] [Related]
6. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
[TBL] [Abstract][Full Text] [Related]
7. Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Antoni D; Jastaniah Z; Haoming QC; Gaultier C; Ahle G; Couchot J; Atlani D; Schott R; Clavier JB; Srour R; Chaussemy D; Noël G
Cancer Radiother; 2016 Jun; 20(4):282-91. PubMed ID: 27318555
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
9.
Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
[TBL] [Abstract][Full Text] [Related]
10. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
[TBL] [Abstract][Full Text] [Related]
13. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma.
Combs SE; Edler L; Rausch R; Welzel T; Wick W; Debus J
Acta Oncol; 2013 Jan; 52(1):147-52. PubMed ID: 22686472
[TBL] [Abstract][Full Text] [Related]
14. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.
Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583
[TBL] [Abstract][Full Text] [Related]
15. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
[TBL] [Abstract][Full Text] [Related]
16. Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort.
Niyazi M; Flieger M; Ganswindt U; Combs SE; Belka C
Radiat Oncol; 2014 Jun; 9():128. PubMed ID: 24893775
[TBL] [Abstract][Full Text] [Related]
17. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030
[TBL] [Abstract][Full Text] [Related]
18. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M
J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828
[TBL] [Abstract][Full Text] [Related]
19. Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
Straube C; Elpula G; Gempt J; Gerhardt J; Bette S; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE
Strahlenther Onkol; 2017 Nov; 193(11):897-909. PubMed ID: 28616821
[TBL] [Abstract][Full Text] [Related]
20. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
